Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort

Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology Vol. 94; no. 11; pp. 5260 - 5270
Main Authors: Cardeñoso Domingo, Laura, Roy Vallejo, Emilia, Zurita Cruz, Nelly D., Chicot Llano, Marta, Ávalos Pérez‐Urria, Elena, Barrios, Ana, Hernando Santos, Julia, Ortiz, Javier, Rodríguez García, Sebastián C., Martín Ramírez, Alexandra, Ciudad Sañudo, Marianela, Marcos, Celeste, García Castillo, Elena, Fontán García‐Rodrigo, Leticia, González, Begoña, Méndez, Rosa, Iturrate, Isabel, Sanz García, Ancor, Villa, Almudena, Sánchez Azofra, Ana, Quicios, Begoña, Arribas, David, Álvarez Rodríguez, Jesús, Patiño, Pablo, Trigueros, Marina, Uriarte, Miren, Triguero Martínez, Ana, Arévalo, Cristina, Galván Román, José M., García‐Vicuña, Rosario, Ancochea, Julio, Soriano, Joan B., Canabal, Alfonso, Muñoz Calleja, Cecilia, De la Cámara, Rafael, Suarez Fernández, Carmen, González Álvaro, Isidoro, Rodríguez‐Serrano, Diego A.
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01-11-2022
John Wiley and Sons Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Summary Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients.
AbstractList Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort.
Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV ( N  = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), ( p  < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p  = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p  < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p  < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients.
Early kinetics of SARS-CoV-2 viral load (VL) in plasma determined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single-center study including consecutive adult patients hospitalized with COVID-19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT-PCR was performed to assess SARS-CoV-2 VL. The main outcomes were in-hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID-19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU-admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1-15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3-28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8-22]; p < 0.0001). Relevant SARS-CoV-2 viremia in the first week of hospitalization was associated with higher in-hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort.
Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Summary Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients.
Author Rodríguez García, Sebastián C.
Sanz García, Ancor
Quicios, Begoña
Arribas, David
Marcos, Celeste
Patiño, Pablo
Rodríguez‐Serrano, Diego A.
García‐Vicuña, Rosario
Soriano, Joan B.
Galván Román, José M.
Cardeñoso Domingo, Laura
Martín Ramírez, Alexandra
Uriarte, Miren
García Castillo, Elena
Roy Vallejo, Emilia
Sánchez Azofra, Ana
Ortiz, Javier
Muñoz Calleja, Cecilia
Iturrate, Isabel
Ancochea, Julio
Villa, Almudena
Trigueros, Marina
Arévalo, Cristina
Ávalos Pérez‐Urria, Elena
Hernando Santos, Julia
González, Begoña
Canabal, Alfonso
Suarez Fernández, Carmen
Méndez, Rosa
De la Cámara, Rafael
Zurita Cruz, Nelly D.
Chicot Llano, Marta
Barrios, Ana
Álvarez Rodríguez, Jesús
Fontán García‐Rodrigo, Leticia
Ciudad Sañudo, Marianela
Triguero Martínez, Ana
González Álvaro, Isidoro
AuthorAffiliation 6 Hematology Department Hospital Universitario La Princesa Madrid Spain
8 Methodology Unit. Health Research Institute. Hospital Universitario La Princesa IIS‐IP Madrid Spain
2 Internal Medicine Department Hospital Universitario La Princesa Madrid Spain
10 Present address: Intensive Care Unit, Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain
3 Intensive Care Unit, Hospital Universitario La Princesa Madrid Spain
4 Pneumology Department Hospital Universitario La Princesa Madrid Spain
5 Anesthesiology Department Hospital Universitario La Princesa Madrid Spain
9 Immunology Department Hospital Universitario La Princesa Madrid Spain
1 Microbiology Department Hospital Universitario La Princesa Madrid Spain
7 Rheumathology Department Hospital Universitario La Princesa Madrid Spain
AuthorAffiliation_xml – name: 7 Rheumathology Department Hospital Universitario La Princesa Madrid Spain
– name: 1 Microbiology Department Hospital Universitario La Princesa Madrid Spain
– name: 2 Internal Medicine Department Hospital Universitario La Princesa Madrid Spain
– name: 4 Pneumology Department Hospital Universitario La Princesa Madrid Spain
– name: 6 Hematology Department Hospital Universitario La Princesa Madrid Spain
– name: 10 Present address: Intensive Care Unit, Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain
– name: 3 Intensive Care Unit, Hospital Universitario La Princesa Madrid Spain
– name: 5 Anesthesiology Department Hospital Universitario La Princesa Madrid Spain
– name: 9 Immunology Department Hospital Universitario La Princesa Madrid Spain
– name: 8 Methodology Unit. Health Research Institute. Hospital Universitario La Princesa IIS‐IP Madrid Spain
Author_xml – sequence: 1
  givenname: Laura
  surname: Cardeñoso Domingo
  fullname: Cardeñoso Domingo, Laura
  email: lauramaria.cardenoso@salud.madrid.org, lacado@gmail.com
  organization: Hospital Universitario La Princesa
– sequence: 2
  givenname: Emilia
  surname: Roy Vallejo
  fullname: Roy Vallejo, Emilia
  organization: Hospital Universitario La Princesa
– sequence: 3
  givenname: Nelly D.
  surname: Zurita Cruz
  fullname: Zurita Cruz, Nelly D.
  organization: Hospital Universitario La Princesa
– sequence: 4
  givenname: Marta
  surname: Chicot Llano
  fullname: Chicot Llano, Marta
  organization: Hospital Universitario La Princesa
– sequence: 5
  givenname: Elena
  surname: Ávalos Pérez‐Urria
  fullname: Ávalos Pérez‐Urria, Elena
  organization: Hospital Universitario La Princesa
– sequence: 6
  givenname: Ana
  surname: Barrios
  fullname: Barrios, Ana
  organization: Hospital Universitario La Princesa
– sequence: 7
  givenname: Julia
  surname: Hernando Santos
  fullname: Hernando Santos, Julia
  organization: Hospital Universitario La Princesa
– sequence: 8
  givenname: Javier
  surname: Ortiz
  fullname: Ortiz, Javier
  organization: Hospital Universitario La Princesa
– sequence: 9
  givenname: Sebastián C.
  surname: Rodríguez García
  fullname: Rodríguez García, Sebastián C.
  organization: Hospital Universitario La Princesa
– sequence: 10
  givenname: Alexandra
  surname: Martín Ramírez
  fullname: Martín Ramírez, Alexandra
  organization: Hospital Universitario La Princesa
– sequence: 11
  givenname: Marianela
  surname: Ciudad Sañudo
  fullname: Ciudad Sañudo, Marianela
  organization: Hospital Universitario La Princesa
– sequence: 12
  givenname: Celeste
  surname: Marcos
  fullname: Marcos, Celeste
  organization: Hospital Universitario La Princesa
– sequence: 13
  givenname: Elena
  surname: García Castillo
  fullname: García Castillo, Elena
  organization: Hospital Universitario La Princesa
– sequence: 14
  givenname: Leticia
  surname: Fontán García‐Rodrigo
  fullname: Fontán García‐Rodrigo, Leticia
  organization: Hospital Universitario La Princesa
– sequence: 15
  givenname: Begoña
  surname: González
  fullname: González, Begoña
  organization: Hospital Universitario La Princesa
– sequence: 16
  givenname: Rosa
  surname: Méndez
  fullname: Méndez, Rosa
  organization: Hospital Universitario La Princesa
– sequence: 17
  givenname: Isabel
  surname: Iturrate
  fullname: Iturrate, Isabel
  organization: Hospital Universitario La Princesa
– sequence: 18
  givenname: Ancor
  surname: Sanz García
  fullname: Sanz García, Ancor
  organization: Hospital Universitario La Princesa
– sequence: 19
  givenname: Almudena
  surname: Villa
  fullname: Villa, Almudena
  organization: Hospital Universitario La Princesa
– sequence: 20
  givenname: Ana
  surname: Sánchez Azofra
  fullname: Sánchez Azofra, Ana
  organization: Hospital Universitario La Princesa
– sequence: 21
  givenname: Begoña
  surname: Quicios
  fullname: Quicios, Begoña
  organization: Hospital Universitario La Princesa
– sequence: 22
  givenname: David
  surname: Arribas
  fullname: Arribas, David
  organization: Hospital Universitario La Princesa
– sequence: 23
  givenname: Jesús
  surname: Álvarez Rodríguez
  fullname: Álvarez Rodríguez, Jesús
  organization: Hospital Universitario La Princesa
– sequence: 24
  givenname: Pablo
  surname: Patiño
  fullname: Patiño, Pablo
  organization: Hospital Universitario La Princesa
– sequence: 25
  givenname: Marina
  surname: Trigueros
  fullname: Trigueros, Marina
  organization: Hospital Universitario La Princesa
– sequence: 26
  givenname: Miren
  surname: Uriarte
  fullname: Uriarte, Miren
  organization: Hospital Universitario La Princesa
– sequence: 27
  givenname: Ana
  surname: Triguero Martínez
  fullname: Triguero Martínez, Ana
  organization: Hospital Universitario La Princesa
– sequence: 28
  givenname: Cristina
  surname: Arévalo
  fullname: Arévalo, Cristina
  organization: Hospital Universitario La Princesa
– sequence: 29
  givenname: José M.
  surname: Galván Román
  fullname: Galván Román, José M.
  organization: Hospital Universitario La Princesa
– sequence: 30
  givenname: Rosario
  surname: García‐Vicuña
  fullname: García‐Vicuña, Rosario
  organization: Hospital Universitario La Princesa
– sequence: 31
  givenname: Julio
  surname: Ancochea
  fullname: Ancochea, Julio
  organization: Hospital Universitario La Princesa
– sequence: 32
  givenname: Joan B.
  surname: Soriano
  fullname: Soriano, Joan B.
  organization: Hospital Universitario La Princesa
– sequence: 33
  givenname: Alfonso
  surname: Canabal
  fullname: Canabal, Alfonso
  organization: Hospital Universitario La Princesa
– sequence: 34
  givenname: Cecilia
  surname: Muñoz Calleja
  fullname: Muñoz Calleja, Cecilia
  organization: Hospital Universitario La Princesa
– sequence: 35
  givenname: Rafael
  surname: De la Cámara
  fullname: De la Cámara, Rafael
  organization: Hospital Universitario La Princesa
– sequence: 36
  givenname: Carmen
  surname: Suarez Fernández
  fullname: Suarez Fernández, Carmen
  organization: Hospital Universitario La Princesa
– sequence: 37
  givenname: Isidoro
  surname: González Álvaro
  fullname: González Álvaro, Isidoro
  organization: Hospital Universitario La Princesa
– sequence: 38
  givenname: Diego A.
  surname: Rodríguez‐Serrano
  fullname: Rodríguez‐Serrano, Diego A.
  organization: Hospital Universitario La Princesa
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35811284$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAQxy1URLeFAy-ALHGBQ1p_JbE5IFXLV1FRUQt7tWxnlvUqiRc7SbU3HoFn5Elw2aUCJC7jw_z0mxn_j9BBH3pA6DElJ5QQdrruphNWK6nuoRklqioUqekBmhEqqqKqaHmIjlJaE0KkYuwBOuSlpJRJMUPTFbQwmX7A12dX1z--fZ-HRa4MTz5C5w32CZuUgvNmgAbf-GGF55eL81cZogonmCD6YfsCf4whbcANfgLswirEAadhbLbY9A2eTOsbM_jQ73sP0f2laRM82r_H6POb15_m74qLy7fn87OLwgnBVSEUZby01jJmSwZO5QOsM8KAAsEINTWIRoIEqHjNl85yW1oKspLSLStu-TF6ufNuRttB46Afomn1JvrOxK0Oxuu_O71f6S9h0ooLxWuRBc_2ghi-jpAG3fnkoG1ND2FMmuVRRFaC3KJP_0HXYYx9Pk-zmnJGqaIkU893lMsfliIs75ahRN-mqXOa-leamX3y5_Z35O_4MnC6A258C9v_m_T7D4ud8ic6Qq97
CitedBy_id crossref_primary_10_1007_s10096_023_04627_4
crossref_primary_10_3389_fmed_2023_1215246
crossref_primary_10_1021_acs_analchem_4c02105
crossref_primary_10_1097_CCE_0000000000001109
crossref_primary_10_1016_j_ajog_2022_10_001
crossref_primary_10_1002_jmv_28381
crossref_primary_10_1002_cti2_1468
crossref_primary_10_1016_j_chom_2022_11_016
Cites_doi 10.1186/s12879-021-05886-2
10.1016/S0140-6736(20)30566-3
10.1016/j.jinf.2020.11.024
10.1038/s41598-021-92497-1
10.1093/cid/ciab686
10.1128/JCM.00075-21
10.1093/cid/ciaa1285
10.1093/cid/ciaa1196
10.1016/j.jaci.2020.09.018
10.1186/s13054-020-03398-0
10.1038/s41467-020-19057-5
10.1016/j.lfs.2020.117788
10.1093/cid/ciaa1054
10.1093/cid/ciaa1338
10.1038/s41467-021-23494-1
10.1016/j.healun.2020.03.012
10.1016/j.jinf.2021.06.020
10.1038/s41598-021-86500-y
10.1016/j.jmoldx.2020.10.007
10.1007/s40265-020-01421-w
10.1093/jac/dkab093
10.1080/07853890.2022.2031274
10.1016/j.jviromet.2021.114411
10.1016/j.diagmicrobio.2021.115595
10.1093/cid/ciab394
10.1093/cid/ciaa1315
10.1093/ofid/ofab509
10.1016/j.jcv.2022.105166
ContentType Journal Article
Copyright 2022 The Authors. published by Wiley Periodicals LLC.
2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
This article is protected by copyright. All rights reserved.
Copyright_xml – notice: 2022 The Authors. published by Wiley Periodicals LLC.
– notice: 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
– notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: This article is protected by copyright. All rights reserved.
CorporateAuthor PREDINMUN-COVID Group
the PREDINMUN‐COVID Group
CorporateAuthor_xml – name: PREDINMUN-COVID Group
– name: the PREDINMUN‐COVID Group
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
DOI 10.1002/jmv.27989
DatabaseName Wiley-Blackwell Open Access Collection
Wiley-Blackwell Backfiles (Open access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
CrossRef
MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate CARDEÑOSO DOMINGO et al
EISSN 1096-9071
EndPage 5270
ExternalDocumentID 10_1002_jmv_27989
35811284
JMV27989
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GrantInformation_xml – fundername: The work of Emilia Roy Vallejo has been funded by a Rio‐Hortega grant CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co‐funded by The European Regional Development Fund (ERDF) “A way to make Europe”. The sponsor has not had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WIN
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c4439-491235bbb22b52ec9089bca4ae9e4201a7e4d8e8ee6373fcb3b5b1e8688cf63b3
IEDL.DBID 33P
ISSN 0146-6615
IngestDate Tue Sep 17 20:55:54 EDT 2024
Sat Aug 17 00:40:15 EDT 2024
Thu Oct 10 22:02:18 EDT 2024
Thu Nov 21 21:19:57 EST 2024
Sat Sep 28 08:21:16 EDT 2024
Sat Aug 24 01:02:25 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords COVID-19
poor outcome
SARS-CoV-2
disease severity
viremia
Language English
License Attribution-NonCommercial-NoDerivs
2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Open access.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4439-491235bbb22b52ec9089bca4ae9e4201a7e4d8e8ee6373fcb3b5b1e8688cf63b3
Notes Senior authorship
Laura Cardeñoso Domingoand Emilia Roy Vallejo contributed equally to this study.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
These authors have contributed equally
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.27989
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27989
PMID 35811284
PQID 2713211910
PQPubID 105515
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349374
proquest_miscellaneous_2688086404
proquest_journals_2713211910
crossref_primary_10_1002_jmv_27989
pubmed_primary_35811284
wiley_primary_10_1002_jmv_27989_JMV27989
PublicationCentury 2000
PublicationDate November 2022
PublicationDateYYYYMMDD 2022-11-01
PublicationDate_xml – month: 11
  year: 2022
  text: November 2022
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
– name: Hoboken
PublicationTitle Journal of medical virology
PublicationTitleAlternate J Med Virol
PublicationYear 2022
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2021; 8
2021; 21
2022; 152
2021; 23
2021; 147
2020; 80
2020; 39
2020; 323
2020; 11
2021; 72
2021; 73
2021; 59
2021; 76
2021; 12
2021; 11
2022
2020; 73
2020; 395
2020; 24
2022; 74
2020; 254
2022; 54
2021; 83
2022; 300
2022; 102
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_22_1
e_1_2_9_21_1
Wang W (e_1_2_9_8_1) 2020; 323
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 102
  issue: 3
  year: 2022
  article-title: Duration of SARS‐CoV‐2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID‐19: a cohort study
  publication-title: Diagn Microbiol Infect Dis
– volume: 83
  start-page: 38
  issue: 3
  year: 2021
  article-title: SARS‐CoV‐2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load
  publication-title: J Infect
– volume: 80
  start-page: 1929
  year: 2020
  end-page: 1946
  article-title: Immune therapy, or antiviral therapy, or both for COVID‐19: a systematic review
  publication-title: Drugs
– volume: 74
  start-page: 218
  issue: 2
  year: 2022
  end-page: 226
  article-title: SARS‐CoV‐2 RNAemia predicts clinical deterioration and extrapulmonary complications from COVID‐19
  publication-title: Clin Infect Dis
– volume: 76
  start-page: 1962
  issue: 8
  year: 2021
  end-page: 1968
  article-title: Clinical efficacy and safety of remdesivir in patients with COVID‐19: a systematic review and network meta‐analysis of randomized controlled trials
  publication-title: J Antimicrob Chemother
– volume: 152
  year: 2022
  article-title: Usefulness of real‐time RT‐PCR to understand the kinetics of SARS‐CoV‐2 in blood: a prospective study
  publication-title: J Clin Virol
– volume: 21
  start-page: 184
  year: 2021
  article-title: SARS‐CoV‐2 RNA in plasma samples of COVID‐19 affected individuals: a cross‐sectional proof‐of‐concept study
  publication-title: BMC Infect Dis
– volume: 59
  start-page: e0007521
  issue: 7
  year: 2021
  article-title: Sars‐cov‐2 E gene variant alters analytical sensitivity characteristics of viral detection using a commercial reverse transcription‐PCR assay
  publication-title: J Clin Microbiol
– volume: 72
  start-page: e690
  issue: 10
  year: 2021
  end-page: e691
  article-title: Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in blood of critically ill patients
  publication-title: Clin Infect Dis
– volume: 12
  start-page: 1
  issue: 1
  year: 2021
  end-page: 17
  article-title: SARS‐CoV‐2 RNAemia and proteomic trajectories inform prognostication in COVID‐19 patients admitted to intensive care
  publication-title: Nat Commun
– volume: 323
  start-page: 1843
  issue: 18
  year: 2020
  end-page: 1844
  article-title: Detection of SARS‐CoV‐2 in different types of clinical specimens
  publication-title: JAMA
– volume: 72
  start-page: e291
  issue: 9
  year: 2021
  end-page: e295
  article-title: High frequency of SARS‐CoV‐2 RNAemia and association with severe disease
  publication-title: Clin Infect Dis
– volume: 73
  start-page: e799
  issue: 3
  year: 2021
  end-page: e802
  article-title: Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019
  publication-title: Clin Infect Dis
– volume: 74
  start-page: 1525
  issue: 9
  year: 2022
  end-page: 1533
  article-title: Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes
  publication-title: Clin Infect Dis
– volume: 11
  start-page: 7163
  issue: 1
  year: 2021
  article-title: The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID‐19 patients
  publication-title: Sci Rep
– volume: 254
  year: 2020
  article-title: The role of biomarkers in diagnosis of COVID‐19—a systematic review
  publication-title: Life Sci
– volume: 11
  start-page: 5493
  issue: 1
  year: 2020
  article-title: SARS‐CoV‐2 viral load is associated with increased disease severity and mortality
  publication-title: Nat Commun
– volume: 147
  start-page: 72
  issue: 1
  year: 2021
  end-page: 80
  article-title: IL‐6 serum levels predict severity and response to tocilizumab in COVID‐19: an observational study
  publication-title: J Allergy Clin Immunol
– volume: 24
  start-page: 1
  issue: 1
  year: 2020
  end-page: 13
  article-title: Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID‐19
  publication-title: Crit Care
– volume: 73
  start-page: e2995‐
  issue: 9
  year: 2021
  article-title: SARS‐CoV‐2 RNA in serum as predictor of severe outcome in COVID‐19: A retrospective cohort study
  publication-title: Clin Infect Dis
– volume: 8
  year: 2021
  article-title: Blood SARS‐CoV‐2 RNA load predicts outcome • OFID • 1 SARS‐CoV‐2 blood RNA load predicts outcome in critically ill COVID‐19 patients
  publication-title: Open Forum Infect Dis
– volume: 395
  start-page: 1054
  issue: 10229
  year: 2020
  end-page: 1062
  article-title: Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study
  publication-title: The Lancet
– volume: 300
  year: 2022
  article-title: Evaluation of two RT‐PCR techniques for SARS‐CoV‐2 RNA detection in serum for microbiological diagnosis
  publication-title: J Virol Methods
– volume: 39
  start-page: 405
  issue: 5
  year: 2020
  end-page: 407
  article-title: COVID‐19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal
  publication-title: J Heart Lung Transplant
– volume: 23
  start-page: 10
  issue: 1
  year: 2021
  end-page: 18
  article-title: Dynamics of blood viral load is strongly associated with clinical outcomes in coronavirus disease 2019 (COVID‐19) patients
  publication-title: J Mol Diagn
– year: 2022
– volume: 73
  start-page: 2890
  year: 2020
  article-title: Highly sensitive quantification of plasma severe acute respiratory syndrome coronavirus 2 RNA sheds light on its potential clinical value
  publication-title: Clin Infect Dis
– volume: 83
  start-page: 381
  year: 2021
  end-page: 412
  article-title: Lower respiratory tract and plasma SARS‐CoV‐2 RNA load in critically ill adult COVID‐19 patients: relationship with biomarkers of disease severity
  publication-title: J Infect
– volume: 11
  start-page: 1
  issue: 1
  year: 2021
  end-page: 11
  article-title: Detection of SARS‐CoV‐2 RNA in serum is associated with increased mortality risk in hospitalized COVID‐19 patients
  publication-title: Sci Rep
– volume: 54
  start-page: 524
  issue: 1
  year: 2022
  end-page: 540
  article-title: Emerging COVID‐19 variants and their impact on SARS‐CoV‐2 diagnosis, therapeutics and vaccines
  publication-title: Ann Med
– ident: e_1_2_9_20_1
  doi: 10.1186/s12879-021-05886-2
– ident: e_1_2_9_3_1
  doi: 10.1016/S0140-6736(20)30566-3
– ident: e_1_2_9_6_1
  doi: 10.1016/j.jinf.2020.11.024
– ident: e_1_2_9_7_1
  doi: 10.1038/s41598-021-92497-1
– ident: e_1_2_9_16_1
  doi: 10.1093/cid/ciab686
– ident: e_1_2_9_25_1
– ident: e_1_2_9_34_1
  doi: 10.1128/JCM.00075-21
– ident: e_1_2_9_11_1
  doi: 10.1093/cid/ciaa1285
– ident: e_1_2_9_10_1
  doi: 10.1093/cid/ciaa1196
– ident: e_1_2_9_4_1
  doi: 10.1016/j.jaci.2020.09.018
– ident: e_1_2_9_13_1
  doi: 10.1186/s13054-020-03398-0
– ident: e_1_2_9_12_1
  doi: 10.1038/s41467-020-19057-5
– ident: e_1_2_9_5_1
  doi: 10.1016/j.lfs.2020.117788
– ident: e_1_2_9_9_1
  doi: 10.1093/cid/ciaa1054
– ident: e_1_2_9_18_1
  doi: 10.1093/cid/ciaa1338
– ident: e_1_2_9_2_1
– ident: e_1_2_9_24_1
– ident: e_1_2_9_30_1
  doi: 10.1038/s41467-021-23494-1
– ident: e_1_2_9_26_1
  doi: 10.1016/j.healun.2020.03.012
– ident: e_1_2_9_32_1
  doi: 10.1016/j.jinf.2021.06.020
– ident: e_1_2_9_17_1
  doi: 10.1038/s41598-021-86500-y
– ident: e_1_2_9_19_1
  doi: 10.1016/j.jmoldx.2020.10.007
– ident: e_1_2_9_27_1
  doi: 10.1007/s40265-020-01421-w
– ident: e_1_2_9_29_1
  doi: 10.1093/jac/dkab093
– ident: e_1_2_9_33_1
  doi: 10.1080/07853890.2022.2031274
– ident: e_1_2_9_22_1
– volume: 323
  start-page: 1843
  issue: 18
  year: 2020
  ident: e_1_2_9_8_1
  article-title: Detection of SARS‐CoV‐2 in different types of clinical specimens
  publication-title: JAMA
  contributor:
    fullname: Wang W
– ident: e_1_2_9_23_1
  doi: 10.1016/j.jviromet.2021.114411
– ident: e_1_2_9_28_1
  doi: 10.1016/j.diagmicrobio.2021.115595
– ident: e_1_2_9_31_1
  doi: 10.1093/cid/ciab394
– ident: e_1_2_9_14_1
  doi: 10.1093/cid/ciaa1315
– ident: e_1_2_9_15_1
  doi: 10.1093/ofid/ofab509
– ident: e_1_2_9_21_1
  doi: 10.1016/j.jcv.2022.105166
SSID ssj0008922
Score 2.4684412
Snippet Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a...
Early kinetics of SARS-CoV-2 viral load (VL) in plasma determined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) was evaluated as a...
Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 5260
SubjectTerms Adult
Cohort analysis
COVID-19
COVID-19 - diagnosis
disease severity
Hospitalization
Humans
Mortality
Patients
Polymerase chain reaction
poor outcome
Prospective Studies
Retrospective Studies
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Viremia
Virology
Title Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27989
https://www.ncbi.nlm.nih.gov/pubmed/35811284
https://www.proquest.com/docview/2713211910
https://search.proquest.com/docview/2688086404
https://pubmed.ncbi.nlm.nih.gov/PMC9349374
Volume 94
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BD4gL5Z-UggziwCV0azuxDadq26ogFaourLhFdjIrtlKz1W53z32EPiNPwozzA6sKCYlLFMkTxfKMPWOPv28A3vjSG-VsSLPK51zCDFPHtyy0QadLOdA6YmGORubzd7t_wDQ5HzosTMMP0R-48cyI6zVPcB8WO79JQ8_OV--kcZbBe7RLiPANddKvwtY1GQRaCVLyQVnHKjSQO_2X677oRoB5857kn_FrdECHm__V9ftwr407xV5jKA_gFtYP4c5xm1l_BKtTBprTMIvR3uno59X1cDampxQrWhPPp15MF8K3qsRK8PGtGH4Zf9wnoV0nyL8il8F7L07msw69Kbj67vxSRApb4etKkFlPmyJObdtj-HZ48HV4lLY1GdJSa04aOwbXhhCkDJnEktOGofTao0NNwYQ3qCuLFjFXRk3KoEIWdtHm1paTXAX1BDbqWY3PQGhTadrcVJnPvY6BKksanGR2oipZJvC6005x0VBvFA3JsixoBIs4gglsd3or2tm3oBbaYzNz3SCBV30zzRtOhvgaZ0uSoR7Rdk4PdAJPGzX3f2FOOPbbCZg1A-gFmJN7vaWe_ojc3E5pCvjoy7fRAP7e8eLT8Ti-bP276HO4Kxl9EaGQ27BxOV_iC7i9qJYvo_H_ArdHCrc
link.rule.ids 230,315,782,786,887,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB7RIgEXoDwXChjUQy9LU9u7thGXKm2VlqatmjbitrJ3HRGkblDS5MxP6G_sL2HG-4CoQkLislrJs1rL87TH8w3Ahs2tEka7OClsSi3MfGzoloVU3sicd6QMtTC9gTr-qnf3CCbnc1MLU-FDtAdupBnBXpOC04H01m_U0O-Xi49cGW1W4K5MURCpgEOctnZYmyqHgLYgRi-UNLhCHb7VfrrsjW6FmLdvSv4ZwQYXtP_o_yb_GB7WoSfbqWRlDe748gnc69fJ9aewOKNac1xpNtg5G9z8vO5OhvjkbIFm8XJs2XjGbM1NXzA6wWXdk-HBLhJtG4Yu1lMnvE_sdDppCjgZNeCdXrGAYstsWTCU7HHVx6keewYX-3vn3V5ct2WIcykpb2yovtY5x7lLuM8pc-hyK603XmI8YZWXhfba-1QoMcqdcInb9jrVOh-lwonnsFpOSv8SmFSFxP1NkdjUyhCrEqXyo0SPRMHzCD407Ml-VOgbWYWzzDNcwSysYATrDeOyWgFnOILbbAKv60Twvh1G1aF8iC39ZI40OCPc0cmOjOBFxef2LwQLR647ArUkAS0BwXIvj5TjbwGe2wiJMR9-uRkk4O8Tzw77w_Dy6t9J38H93nn_KDs6OP7yGh5wKsYIlZHrsHo1nfs3sDIr5m-DJvwCcBsO3w
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlVceD9SChjEgUvo1nYSG07Vblct0LLqwqq3yI4dsZWarXa7e-Yn8Bv5Jcw4D1hVSEhcokieKJbnaY_nG4DXpjCZ0MrGiTMptTDzsaZbFjLzWha8J2WohTkcZydnanBAMDnv21qYGh-iO3AjzQj2mhT80pW7v0FDzy9Wb3mmld6AmxLDcALOF2LUmWGl6xQCmoIYnVDSwgr1-G736bozuhZhXr8o-WcAGzzQ8M5_zf0u3G4CT7ZfS8o9uOGr-7B13KTWH8DqlCrNcZ3ZeP90_PP7j_5sgk_OVmgUL6aGTRfMNLz0jtH5Let_nhwNkGhPM3SwnvrgvWOj-awt32TUfnd-xQKGLTOVYyjX07qLUzP2EL4OD770D-OmKUNcSElZY03VtdZazm3CfUF5Q1sYabz2EqMJk3nplFfepyITZWGFTeyeV6lSRZkKKx7BZjWr_BNgMnMSdzcuMamRIVIlysyXiSqF40UEr1ru5Jc19kZeoyzzHFcwDysYwU7Lt7xRvwWO4CaboOt6EbzshlFxKBtiKj9bIg3OCPdzsicjeFyzufsLgcKR444gWxOAjoBAuddHqum3AM6thcSID798EwTg7xPPPxxPwsv2v5O-gK3RYJh_Ojr5-BRucarECGWRO7B5NV_6Z7CxcMvnQQ9-ASoIDYU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relevant+SARS%E2%80%90CoV%E2%80%902+viremia+is+associated+with+COVID%E2%80%9019+severity%3A+Prospective+cohort+study+and+validation+cohort&rft.jtitle=Journal+of+medical+virology&rft.au=Carde%C3%B1oso+Domingo%2C+Laura&rft.au=Roy+Vallejo%2C+Emilia&rft.au=Zurita+Cruz%2C+Nelly+D.&rft.au=Chicot+Llano%2C+Marta&rft.date=2022-11-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=94&rft.issue=11&rft.spage=5260&rft.epage=5270&rft_id=info:doi/10.1002%2Fjmv.27989&rft.externalDBID=10.1002%252Fjmv.27989&rft.externalDocID=JMV27989
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon